Coya Therapeutics Stock Forum

$Coya Therapeutics (COYA.US)$ Reuters· 1 min ago
Coya Therapeutics Announces Subcutaneously Administered Coya 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease

$Coya Therapeutics (COYA.US)$
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
Coya Therapeutics (NASDAQ: COYA) announces promising results for COYA 302, a subcutaneously administered anti-inflammatory biologic, in a preclinical Parkinson's disease (PD) mouse model. The study shows that COYA 302significantly reduces neuroinflammation in key brain regions affected b...

$Coya Therapeutics (COYA.US)$
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
Coya Therapeutics (NASDAQ: COYA) has announced that results from a double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease will be presented at the Clinical Trials on...

$Coya Therapeutics (COYA.US)$
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Coya Therapeutics (NASDAQ: COYA) has filed for intellectual property protectionfor the combination of COYA 301 (low-dose interleukin-2) and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs).
This combination aims to enhance regulatory T cell function and may offer a mul...

$Coya Therapeutics (COYA.US)$ Reuters· just
Coya Therapeutics : Got Notification From FDA Stating That Additional Non-Clinical Data Is Required Prior to Initiation of Coya 302 ALS Study

$Coya Therapeutics (COYA.US)$ Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute Along With Funding From the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform Into the Clinic

$Coya Therapeutics (COYA.US)$ Coya Therapeutics Announces Publication Of Phase 1 Study On CTLA4-Ig And Interleukin-2 Combination Therapy For ALS In Frontiers In Neurology
Benzinga· 2 mins ago
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced Regulatory T cell (Treg) number and suppressive function in patients who were administered a combinatio...

$Coya Therapeutics (COYA.US)$
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
Coya Therapeutics (NASDAQ: COYA) announced the acceptance of a peer-reviewed manuscript in Frontiers in Neurology. The study, titled 'A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,' highlights the halting of ALS p...

$Coya Therapeutics (COYA.US)$
NEWS
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Positive
Completion of Phase 2 study on schedule.
Study funded by the Gates Foundation and Alzheimer’s Association, indicating strong support.
Topline results expected by summer 2024.
Preliminary data showed significant improvements in cognitive function.
Significant enhancement in regulatory T cell (Treg) function and...

$Coya Therapeutics (COYA.US)$ Coya Therapeutics Inc -Phase 2 Top Line Data on Track to Be Reported in Summer of 2024